Company profile
Allarity Therapeutics, Inc.
NASDAQ: ALLR · Healthcare · Biotechnology
#967 of 1,422 Healthcare companies by revenue
EA Score
25DFH 32DQ 12GM —SS 30
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$345.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$11.2M
Employees
8
as of 2026-08-21
Market cap
$22.8M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$320.0k$320.0k2025
Net income-$11.2M-$11.2M2025
Operating income-$12.6M-$12.6M2025
Total assets$18.3M$18.3M2025
Liabilities$8.4M$8.4M2025
Equity$9.8M$9.8M2025
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
Not disclosed.
The read
What is Allarity Therapeutics, Inc.’s revenue?
Allarity Therapeutics, Inc. booked $320.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -3509.7% net margin.
Peers · Healthcare
MedX Health Corp29DProvectus Biopharmaceuticals, Inc.35DGold River Productions, Inc.——Vyome Holdings, Inc.33DInteractive Health Network——Medixall Group, Inc.——Neighbors
Suffolk →Key facts
CEOThomas H. Jensen
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: ALLR
Employees8
IPO date2021-12-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.